PIN48 Cost-Efectiveness Analysis of Darunavir Versus Atazanavir, Each in Combination With Emtricitabine and Tenofovir, for the Management of Naive Anti-Retroviral HIV Infected Patients, Under the Belgian Social Security Perspective

Autor:	Isabelle Borget, M. Santos, W. Ferraq, S. Stenut, J.C. Legrand, P. Tilleul
Rok vydání:	2012
Předmět:	Tenofovir business.industry Health Policy Perspective (graphical) Public Health Environmental and Occupational Health Emtricitabine Virology Atazanavir medicine Hiv infected patients Antiretroviral medication business Darunavir medicine.drug
Zdroj:	Value in Health. 15(7):A393-A394
ISSN:	1098-3015
DOI:	10.1016/j.jval.2012.08.1115
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccfd2bf3dc7807126a23003f55501db9 Zobrazit plný text záznamu Full Text from ScienceDirect